Abbott Laboratories: Organic Growth Will Carry It Through (NYSE:ABT)
Abbott had a visible slowdown in topline and earnings margin starting in 2022 and continued in Q1's data. Read why ABT is a buy at the current prices.
Stay updated with breaking news from Waterside Insight. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abbott had a visible slowdown in topline and earnings margin starting in 2022 and continued in Q1's data. Read why ABT is a buy at the current prices.
Kohl's bet on Sephora hasn't proven successful while the costs and expenses are already high. Click here to see why KSS stock is a Sell.
Williams-Sonoma has had a strong performance and an effective operational model. See why I recommend a hold on WSM stock at this time.
Intuit's vertical integration of its services products has success, with more growth ahead. See why we recommend a Hold rating on INTU stock.
Corning has resilience derived from its leading position in research and development, while its framework gives a stable path in its outlook. See why we rate GLW stock a Hold.